Examination of the cost-effectiveness of rasagiline versus other approved first-line Parkinson disease therapies indicated that rasagiline was either cost saving or cost-effective in all cases.
Christophe Armand, MD
Advertisement
Articles by Christophe Armand, MD
Advertisement
Latest Updated Articles
- Cost-Effectiveness of Rasagiline Compared With First-Line Early Parkinson Disease Therapies
Published: June 9th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
CDC Layoffs Raise Questions About the Future of Public Health Surveillance
2
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
3
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
4
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
5
